title: [Assessment of pharmacological correction in the treatment of patients with systemic lupus erythematosus].
abstract: Systemic lupus erythematosus is a classical example of autoimmune disease. The highest sickness rate is observed among women of a younger age, which has an important medical significance. In recent years, the trends of early morbid affection of kidneys (lupus nephritis) and central nervous system (meningoencephalitis) are observed, especially with the presence of antiphospholipidus syndrome. The Article provides examples of lungs affection with the consequent development of infarction pneumonia, thromboembolism developed into the micro branches of pulmonary artery, and cases of early central nervous system affection. In this connection, It is recommended basic principle of SLE therapy, which is applied on the modern stage. The early use of synchronous therapy is expedient in the presence of serious course of the systemic lupus erythematosus with the system affection and high degree of activity.
authors.forename: T Zh
authors.initials: TZh
authors.lastname: Sultanova
mesh_terms: D000293:Adolescent; D000328:Adult; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010956:Plasmapheresis; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D012720:Severity of Illness Index; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011239:Prednisolone